Clinical trials: Human Healthy Volunteers
Herpes Simplex
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI).
- Trial name
- NCT05298254
- Testing
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Clinical Evaluation of the Magnesium Absorption Kinetics in Human Plasma Upon Oral Intake of Magnesium-based Products
The goal of this clinical trial is to study the effect of four magnesium-based products on the magnesium concentration in plasma of volunteers upon oral intake.
- Trial name
- NCT06225349
- Testing
- Dietary supplementation with Microencapsulated Magnesium, Dietary supplementation with Magnesium Oxide, Dietary supplementation with Magnesium Citrate
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bionos Biotech S.L.
Hepatitis C
Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients
Chronic active hepatitis C viral infections are difficult to treat: current drug therapies can result in severe side effects that some patients will not tolerate.
- Trial name
- NCT00229749
- Testing
- AVI-4065 Injection
- Volunteers
- 80 people
- Sponsor
- Sarepta Therapeutics, Inc.
Hepatitis A
Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule
The aim of this study is to evaluate the persistence of hepatitis A antibodies at 138, 150, 162, 174,186, 198, 210, 222, 234 and 246 months after subjects received their first dose of a 2 dose vaccination schedule of hepatitis A…
- Trial name
- NCT00291876
- Testing
- Havrix™
- Where
- Belgium
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers
The purpose of this study is to investigate the safety and tolerability of ascending single and multiple oral doses of MT-4129 in healthy subjects.
- Trial name
- NCT02953132
- Testing
- MT-4129
- Where
- Netherlands
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Relative Bioavailability
An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers
This is an open-label, balanced, randomized, two-period, crossover, single dose study to compare the relative bioavailability in normal healthy, adult, human subjects under Fed and Fasting conditions.
- Trial name
- NCT06025318
- Testing
- PanCytoVir™
- Where
- India
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- TrippBio, Inc.
Healthy, Idiopathic Inflammatory Myopathies
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases.
- Conditions
- Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease
- Trial name
- NCT07284797
- Testing
- XmAb657
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Healthy Adult Participants, Asthma Exacerbation
RIG 101 Trial in Healthy Adults and Adults With Asthma
Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy
- Conditions
- Healthy Adult Participants, Asthma Exacerbation, Safety and Efficacy
- Trial name
- NCT07488897
- Testing
- RIG-101
- Where
- 2 sites in United Kingdom
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- RIGImmune Inc.
Healthy Volunteers, Down Syndrome
Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
Leucettinib-21 First-in-Human Phase 1 Study in 6 Parts: Single (Part 1 and 5) and Multiple (Part 3 and 6) Ascending Doses, and Food-Effect (Part 2) in Healthy Subjects, and Single Dose (Part 4) in People with Down Syndrome (DS)…
- Conditions
- Healthy Volunteers, Down Syndrome, Alzheimer's Disease
- Trial name
- LEUCETTA (NCT06206824)
- Testing
- Leucettinib-21
- Where
- France
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Perha Pharmaceuticals
Infection, Human Immunodeficiency Virus
A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
This is an open-label, single sequence, 2-cohort, drug-drug interaction study in healthy male and female subjects. There is no formal hypothesis, however, it is expected that the coadministration of BMS-663068 with darunavir…
- Trial name
- NCT02277600
- Testing
- BMS-663068, Darunavir, Cobicistat
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
A Study to Evaluate the Effect of High Fat Meal on Cabotegravir
Cabotegravir is being developed for the treatment of human immunodeficiency virus (HIV) 1 infection. Specifically, it is being developed as a component of a 2-drug maintenance regimen (post-induction of viral suppression) that…
- Trial name
- NCT02799264
- Testing
- Cabotegravir 30 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Influenza, Human
Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)
This is a phase I, double-blind, randomized, placebo-controlled trial with two groups of subjects to receive seasonal trivalent inactivated split virion influenza vaccine (A/H1N1; A/H3N2 and B strains) or placebo (phosphate…
- Trial name
- IVACFLU-S (NCT02598089)
- Testing
- Trivalent Seasonal Influenza Vaccine
- Where
- Vietnam
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Healthy Volunteers
First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers
This first-in-human (FIH) study will provide the first safety and pharmacokinetic (PK) data for G1T38 in humans and will allow further development of G1T38 in patients with cancer.
- Trial name
- NCT02821624
- Testing
- G1T38 (CDK 4/6 Inhibitor)
- Where
- Netherlands
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- G1 Therapeutics, Inc.
Healthy
Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
A dose-block randomized, double-blind, placebo-controlled, single and multiple ascending dose, first-in-human, phase 1 first in human clinical trial to evaluate the safety, tolerability, and pharmacokinetics after subcutaneous…
- Trial name
- NCT05701644
- Testing
- C1K 150mg, C1K 300mg, C1K 600mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ensol Bioscience
Influenza
Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers
This study assesses safety, tolerability and immunogenicity of NBP607QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease.
- Trial name
- NCT03826719
- Testing
- NBP607QIV, Agrippal
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Rabies
An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)
This is a single-arm, open-label study of Rabies Immune Globulin (Human), Caprylate/Chromatography Purified (RIG-C), in approximately 12 healthy subjects.
- Trial name
- NCT02139657
- Testing
- RIG-C
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Grifols Therapeutics LLC
Healthy
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
The purpose of this study is to demonstrate the non-inferiority of a heterologous prime-boost regimen using Ad26.ZEBOV as prime and MVA-BN-Filo as boost administered at different doses at a 56-day interval versus the same regimen…
- Trial name
- NCT02543567
- Testing
- Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp)
- Where
- 6 sites in United States
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Healthy Volunteers
Evaluation of the Effects of DracoBelle Nu in Skin Health After Oral Intake
The goal of this clinical trial is to study the effects of DracoBelleTM Nu in different skin parameters associated with age. Volunteers will be asked to take either placebo of DracoBelleTM Nu capsules once a day by oral intake…
- Trial name
- NCT06059534
- Testing
- Dietary supplementation with DracoBelleTM Nu.
- Where
- Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bionos Biotech S.L.
Healthy
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fed Conditions
Objective: Primary objective of the present study was to compare the single dose bioequivalence of Torrent's Quetiapine Fumarate Tablets 1 × 25 mg. Dosing periods of the study were separated by a washout period of 7 days.
- Trial name
- NCT01634399
- Testing
- Torrent's Quetiapine Fumarate Tablets
- Where
- India
- Volunteers
- healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Hereditary Angioedema (HAE)
A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects
The purpose of this study is to assess the safety and tolerability of the study drug (DX-2930) administered subcutaneously in healthy subjects. Subjects will be randomized to receive DX-2930 or placebo.
- Trial name
- NCT01923207
- Testing
- DX-2930
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Shire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.